ICTI Biostatistics Expert to Speak at International Conference
Continuing ICTI’s leadership in Adaptive Clinical Trial Design and Implementation, ICTI’s Manager of Biostatistics, Eva Miller, Ph.D., has been invited to present at the upcoming meeting of the International Society for Analysis, its Applications, and Computation (ISAAC).
Yardley, PA – July 19, 2005 – Continuing ICTI's leadership in Adaptive Clinical Trial Design and Implementation, ICTI's Manager of Biostatistics, Eva Miller, Ph.D., has been invited to present at the upcoming meeting of the International Society for Analysis, its Applications, and Computation (ISAAC). The 5Th annual conference, being held July 25-30, 2005 in Catania, Italy, includes a sub-session on Mathematical Biology and Medicine, in which Dr. Miller will present her talk, "Implementation of Adaptive Randomizations for Clinical Trials."
Because of the efficiencies they allow, adaptive trial designs are increasingly being used by both small biotechs and large pharmaceutical companies. Adaptive randomizations, a type of adaptive trial design, are especially valuable when study populations are small or when blinding of study drug/device vs. placebo is not possible. They are often used in studies of rare diseases, in oncology studies, and in medical device trials. Dr. Miller's presentation will recount ICTI's experience in working with clients to design and execute adaptive clinical trial designs.
Richard McCann, ICTI's President, noted, "Our unique combination of technologies for real-time clinical trial data capture, along with the capabilities of our sister company Clinical Trial Services (CTS) to provide state-of-the-art clinical supplies management positions ICTI to make adaptive clinical trial designs feasible. We are honored to have our capabilities and experience presented at this prestigious conference."
About ICTI and Almac Sciences
ICTI has been implementing adaptive randomization designs since 1999, and its technologies and services have been used in over 60 adaptive randomization studies. ICTI is a division of Almac Sciences that specializes in interactive solutions to accelerate the clinical trials process and reduce the costs of clinical trials. Our solutions include Interactive Voice Response (iVR) for patient randomization, dosing and clinical supply management; iDiary phone-based patient diaries; iTrial EDC for clinical trials data; and forecasting for clinical trials supplies planning.
Almac Sciences and its affiliated companies (CSS (Chemical Synthesis Services), CTS (Clinical Trial Services), ICTI (Interactive Clinical Technologies Incorporated), PDMS (Pharmaceutical Development and Manufacturing Services) and ArraDx (Array Based Diagnostics)) provide a broad range of services across drug discovery, diagnostics, pharmaceutical research and development, manufacture of API, clinical trials and drug product manufacture. US operations are based in Pennsylvania, North Carolina and California. European operations are headquartered in Craigavon, Northern Ireland with additional operations in London and Edinburgh.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
